Double-blind trial of bestatin in HIV-positive patients

M Hørding, P C Gøtzsche, L Dalh Christensen, Ib Christian Bygbjerg, V Faber

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    4 Citationer (Scopus)

    Abstract

    Twenty-two HIV-positive homosexual men with a moderately impaired immune system were randomized to bestatin capsules 60 mg a day or placebo for 4 weeks. None suffered from opportunistic infections. The immunomodulating effect of bestatin was investigated by lymphocyte proliferation assay with pokeweed mitogen, phytohaemagglutinin, and concanavalin A, surface marker analysis of T-helper/T-suppressor cells by flow cytometry, natural killer cell activity, beta-2-microglobulin and HIV antibody quantitation. No significant differences between bestatin and placebo in immunological, haematological, biochemical or clinical variables were detected.
    OriginalsprogEngelsk
    TidsskriftBiomedicine & Pharmacotherapy
    Vol/bind44
    Udgave nummer9
    Sider (fra-til)475-8
    Antal sider4
    ISSN0753-3322
    StatusUdgivet - 1 jan. 1990

    Citationsformater